This review explores the therapeutic potential of imidazo[1,2-a]pyridine derivatives against cancer, suggesting significant advancements in drug development.
Heterocyclic compounds play a crucial role in medicinal chemistry, with imidazo[1,2-a]pyridine emerging as a significant scaffold due to its broad pharmacological applications. The unique structural framework of imidazo[1,2-a]pyridine allows for strong interactions with biological targets, making it a favorable candidate for anticancer drug development. This review explores the recent advancements in the synthesis, structure-activity relationship (SAR), and mechanistic insights of imidazo[1,2-a]pyridine derivatives as anticancer agents. Various synthetic methodologies, including multicomponent reactions and named transformations, have facilitated the generation of diverse derivatives with potent biological activity. The anticancer properties of these compounds stem from their ability to modulate key signaling pathways, induce apoptosis, and inhibit kinases implicated in tumor progression. Additionally, we discuss cytotoxic evaluations and the therapeutic potential of these derivatives against different cancer cell lines. The review highlights the challenges and future perspectives in optimizing imidazo[1,2-a]pyridine-based compounds for clinical applications, emphasizing their promise as next-generation anticancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: